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Summary
Few effective countermeasures currently exist to deal with chemical, biological,
radiological, and nuclear terror agents.  In early 2003, the Bush administration
proposed Project BioShield to stimulate the development of such countermeasures
and to procure them for the Strategic National Stockpile (SNS).  Congress considered
three bills that incorporated much of the administration’s proposal: S. 15 (Gregg),
H.R. 2122 (Tauzin), and S. 1504 (Gregg).  H.R. 2122 passed the House on July 16,
2003.  S. 15 passed the Senate on May 25, 2004 in an amended form similar to H.R.
2122.  This version of S. 15 passed the House on July 14, 2004.  President Bush
signed S. 15 into law as the Project BioShield Act of 2004 (P.L. 108-276) on July 21,
2004.    
Although many of the details of Project BioShield changed during
Congressional consideration, all the proposals shared similar key provisions.  Each
bill would have provided expedited hiring, procurement, and grant awarding
procedures for bioterrorism-related products and services.  Each bill would have
provided a market guarantee for countermeasure producers by allowing the  Secretary
of Health and Human Services (HHS) to contract to procure countermeasures still in
development.  Thus, several years before a company plans to be able to deliver a
countermeasure, the company would have been assured that if they successfully
develop the countermeasure the government is obligated to purchase a set amount of
it at a set price.  Each bill would have authorized the HHS Secretary to allow the
emergency use of countermeasures that lack Food and Drug Administration approval.
Congress changed many important aspects of the Administration’s proposal.
The most important change related to the funding mechanism.  The Administration
requested a permanent, indefinite appropriation, to be spent at the President’s
discretion, for the purchase of countermeasures.  The enacted version of Project
BioShield authorizes the appropriation of $5.593 billion for FY2004-FY2013.  The
Department of Homeland Security (DHS) Appropriations Act (P.L. 108-90)
appropriated this amount.
The Project BioShield Act of 2004 (P.L. 108-276) also: transfers the SNS from
DHS to HHS, permits procurement of countermeasures with commercial markets,
permits countermeasure procurement contracts to be written up to eight years before
countermeasures are expected to be deliverable, and authorizes appropriations to
allow DHS to improve its ability to perform threat analysis.  A provision that would
have allowed HHS to develop countermeasures directly was excluded from the
enacted version Project BioShield.
This report will not be updated.  For more analysis and the current status of
Project BioShield, see CRS Report RS21507, Project BioShield, by Frank Gottron.
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Introduction
Several high profile incidents since 2001 have highlighted the nation’s
vulnerability to bioterrorism.  Most prominent of these were the anthrax mailings of
2001.  These caused five deaths, required thousands to take prophylactic antibiotics,
and cost millions of dollars to clean up.  If there had not been an effective antibiotic
treatment for this strain of anthrax, the death toll would have been even higher.
Other prominent incidents include the discovery of the toxin ricin in Senator
Frist’s office in the Dirksen Senate Office Building office in February 2004 and in
a postal facility in Greenville, South Carolina, in October 2003.  The Secret Service
also intercepted a letter containing ricin addressed to the White House in October
2003.  Ricin, a deadly toxin, lacks any Food and Drug Administration (FDA)
approved treatments or prophylaxis.1
Many of the other biological threats deemed most dangerous by the Centers for
Disease Control and Prevention (CDC) also lack effective FDA-approved treatments
and  prophylactics.  For example, botulinum toxin, plague, tularemia, and many viral
hemorrhagic fevers (VHFs) lack licensed vaccines, while smallpox and VHFs lack
any specific treatment.2  Additionally, many of the vaccines and treatments that
currently exist are suboptimal for responding to bioterrorism.  For example, the
Department of Health and Human Services (HHS) has called for better vaccines for
anthrax and smallpox and better treatments for anthrax, plague, and botulism.3 
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4 Alan Pemberton, Pharmaceutical Research and Manufacturers of America, Testimony
before the U.S. House of Representatives Select Committee on Homeland Security, May 15,
2003. 
5 Dr. Kim Bush, President Vaccines Division, Baxter Healthcare Corp, Testimony before
the U.S. Senate Committee on Health, Education, Labor, and Pensions, Health
Subcommittee, January 30, 2003.
6 Institute of Medicine and National Research Council, Giving Full Measure to
Countermeasures: Addressing Problems in the DoD Program to Develop Medical
Countermeasures Against Biological Warfare Agents, National Academy Press, Washington
DC, 2004. 
7 See CRS Report RL30913, Pharmaceutical Research and Development: A Description and
Analysis of the Process by Richard Rowberg.
Several factors likely contribute to this paucity of bioterrorism countermeasures,
including a lack of a financial incentives to develop countermeasures,4 the perception
of a relatively high threat of litigation stemming from adverse reactions to the
countermeasures,5 and the lack of success of a Department of Defense effort to
develop such countermeasures.6   In addition, because these diseases are rare, many
companies apparently have balked at spending millions of dollars developing a
product with such a small potential market.7  
To encourage the development of new biomedical countermeasures, President
Bush proposed Project BioShield in his 2003 State of the Union address.  The 108th
Congress considered three bills that incorporated the administration’s proposal: S.
15 (Gregg), H.R. 2122 (Tauzin), and S. 1504 (Gregg).  Most of the attention garnered
by Project BioShield has focused on countermeasures against bioterrorism.
However, Project BioShield also applies to countermeasures against chemical,
radiological, and nuclear attacks.   
This report provides a brief legislative history and a side-by-side comparison of
the three bills, including versions of S. 15 as initially reported and as enacted.  Such
a comparison may be useful both with respect to congressional oversight of Project
BioShield activities and with respect to future legislative initiatives relating to
countermeasure procurement.  
Legislative History
Senate Action.  Senator Gregg introduced S. 15 on March 11, 2003.  The
Senate Committee on Health, Education, Labor, and Pensions (HELP) reported S. 15
on March 25, 2003, with an amendment in the nature of a substitute and without a
written report.  In the comparison tables below, this version is referred to as “S. 15
as Reported by Committee.” 
Senator Gregg introduced S. 1504 on July 30, 2003.  It shared many of the
provisions found in H.R. 2122, which the House had passed on June 16, 2003.  S.
1504  was placed directly on the Senate Legislative Calendar.  In the comparison
tables below, this version is listed as “S. 1504 as Introduced.”
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8 U.S. Congress, Project BioShield Act of 2003: H.Rept. 108-147 Part I, 108th Congress,
first session, pp. 20-21.
On May 19, 2004 the Senate passed S. 15 with an amendment in the nature of
a substitute (99-0).  The amended and passed version of S. 15 had relatively minor
differences from H.R. 2122 (see below).  This version of S. 15 was passed by the
House and became the Project BioShield Act of 2004 (P.L. 108-276).  In the
comparison tables below, this version is referred to as “S. 15 as Enacted.”
House Action.  Representative Tauzin introduced H.R. 2122 on May 15,
2003.   It was referred to the Committee on Energy and Commerce, Committee on
Government Reform, Committee on Armed Services, and the Select Committee on
Homeland Security.  The Committee on the Judiciary chose not to seek a serial
referral.8  
Committee Hearings.  The House Committee on Energy and Commerce
Subcommittee on Health held a joint hearing with the House Select Committee on
Homeland Security Subcommittee on Emergency Preparedness and Response entitled
“Furthering Public Health Security: Project BioShield” on March 27, 2003.  
The House Committee on Government Reform held a hearing to consider the
“Project Bioshield Act” on April 4, 2003.
The House Select Committee on Homeland Security held a hearing on
“BioShield: Countering the Bioterrorist Threat” on May 15, 2003.  The House Select
Committee on Homeland Security Subcommittee on Emergency Preparedness and
Response and the Subcommittee on Intelligence and Counterterrorism held a joint
hearing on “Does the Homeland Security Act of 2002 Give the Department the Tools
It Needs To Determine Which Bio-Warfare Threats Are Most Serious?” on June 5,
2003.  On June 6, 2003 the House Select Committee on Homeland Security held a
hearing on “Bioshield: Lessons from Current Efforts To Develop Bio-Warfare
Countermeasures.”
Committee Reports and Amendments.  The House Committee on Energy
and Commerce reported H.R .2122 (H.Rept. 108-147, Part 1) on June 10, 2003.  The
House Committee on Armed Services discharged H.R. 2122 on June 11, 2003.  The
House Committee on Government Reform reported H.R. 2122 with amendments on
June 12, 2003 (see H.Rept. 108-147, Part 2).  The House Select Committee on
Homeland Security reported H.R. 2122 with amendments on July 8, 2003 (see
H.Rept. 108-147, Part 3).  The version reported by the House Select Committee on
Homeland Security is the version that passed the House.  In the comparison charts
below, this is the version referred to as “H.R. 2122 as Passed by the House.”
Floor Action.  The House of Representatives passed H.R. 2122 on July 16,
2003 (421-2).  The House passed S. 15 on July 14, 2004 (414-2).  
Presidential Action.  S. 15 was signed into law by President Bush on July 21,
2004 (P.L. 108-276).
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Related Legislation.  The Department of Homeland Security Appropriations
Act, 2004 (P.L. 108-90, enacted October 1, 2003) appropriated $5.593 billion for
FY2004-FY2013 to procure medical countermeasures against biological terror
attacks.  Of this amount, up to $890 million may be obligated in FY2004 and no
more than $3.418 billion may be obligated through FY2008.  The enactment of this
law effectively resolved the funding differences that had been pending between S. 15
and H.R. 2122 at that time.  S. 15 as reported by the Senate HELP Committee called
for a permanent indefinite spending appropriation, while H.R. 2122 authorized a
specific appropriation amount.  P.L. 108-90 contained funding levels identical to
those authorized in H.R. 2122.  Although P.L. 108-90 specified that those funds were
only for medical countermeasures against biological terror attacks, the Project
BioShield Act of 2004 (P.L. 108-276) changed this to allow countermeasures against
chemical, biological, radiological, and nuclear terrorism.
The National Defense Authorization Act for Fiscal Year 2004 (P.L. 108-136,
enacted November 24, 2003) contained some Department of Defense-related
language similar to that found in S. 15 as reported by the Senate HELP Committee
and H.R. 2122.  It gave the Secretary of Defense some authorities similar to those
given to the Secretary of Health and Human Services by the Project BioShield Act
of 2004.  These new authorities relate to the hiring of biomedical countermeasure
consultants, the procurement of biomedical countermeasures, and the emergency use
of unapproved countermeasures for the military.  The Defense Secretary’s authorities
relate to Department of Defense programs and military personnel, whereas the HHS
Secretary’s authorities relate to HHS programs and to civilian populations. 
The Consolidated Appropriations Act, 2004 (P.L. 108-199, enacted January 23,
2004), reduced the funds available for obligation in FY2004 from $890 million to
$885 million.
Comparison of the Bills
All of the Project BioShield-related legislative proposals shared the same goal
of increasing the development and purchase of biomedical countermeasures for the
SNS.  Each also largely reflected the Administration’s proposals on a broad scale.
However, Congress, through its deliberative process, changed many of the details in
each bill.
    
Similarities.  These bills shared many provisions.  Each would have provided
expedited hiring, procurement, and grant awarding procedures for bioterrorism-
related products and services.  These provisions were designed to make it easier for
HHS to quickly commit substantial funds to biomedical countermeasure projects.
Each bill would have provided a market guarantee for countermeasure producers by
allowing the HHS Secretary to contract to procure countermeasures still in
development.  Thus,  several years before a company plans to be able to deliver a
countermeasure, the company would be assured that if they successfully develop the
countermeasure the government is obligated to purchase a set amount of it at a set
price.  Under each bill, the manufacturing company can only receive payment upon
countermeasure delivery, with some minor exceptions.   Each bill would have
authorized the HHS Secretary to allow the emergency use of countermeasures that
lack FDA approval.
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9 U.S. Congress. Cost Estimate: S. 15 Project BioShield Act of 2003. Congressional Budget
Office. May 7, 2003.
Differences.  
Funding.  The largest difference among the bills was the difference in funding
mechanism.  S. 15 as reported by the Senate HELP Committee would have granted
a permanent, indefinite appropriation for purchasing countermeasures to be spent at
the President’s discretion.  This mandatory funding, which was also part of the
original Administration proposal, would not be subject to the annual appropriations
process.  The Administration predicted that it would spend approximately $5.6
billion for FY2004-FY2013 for BioShield-related countermeasure procurement.  The
Congressional Budget Office estimated that approximately $8.1 billion would be
spent over that time period.9
H.R. 2122, S. 1504, and S. 15 as amended and enacted authorize specific
funding for the program but do not appropriate funds.  All three of these authorize
the exact appropriation amounts found in the Department of Homeland Security
Appropriation Act, 2004 (P.L. 108-90) that was passed while the Project BioShield
legislation was under consideration.   There were minor differences in the
mechanisms of funding between H.R. 2122 and S. 1504.  S. 15 as enacted adopted
the H.R. 2122 mechanism.
  
SNS Transfer.  Congress created the National Pharmaceutical Stockpile
(NPS),  the forerunner to the SNS, in the Omnibus Consolidated and Emergency
Supplemental Appropriations Act, 1999 (P.L. 105-277).  The Public Health Security
and Bioterrorism Preparedness and Response Act of 2002 (P.L. 107-188) essentially
redesignated the NPS as the SNS and listed specific requirements regarding SNS
management and maintenance.  The Homeland Security Act of 2002 (P.L. 107-296)
transferred the SNS program to the Department of Homeland Security.  S. 15 as
enacted transferred the SNS back to HHS.  This provision was not in any of the other
bills.
 
Countermeasure Qualifications.  The bills differed in which
countermeasures qualify for procurement under Project BioShield.  S. 15 as reported
by the Senate HELP Committee and S. 1504 would have excluded any
countermeasure that has a significant market other than as a countermeasure.  H.R.
2122 and S. 15 as enacted allow the purchase of countermeasures even if they have
other significant markets.  This change may encourage the development of
countermeasures that can protect against more than one agent, such as new wide-
spectrum antibiotics.  Such products are more likely to have other commercial
applications and markets.  Thus, while very desirable for the SNS, they would have
been excluded from Project BioShield funding under S. 15 as reported and S. 1504.
 
S. 15 as reported by the Senate HELP Committee and S. 1504 required that
products be likely to have FDA approval within five years.  H.R. 2122 required that
countermeasures be likely to be approved sometime in the future.  S. 15 as enacted
requires that countermeasures be likely to be approved within eight years.  The
enacted language will allow the HHS Secretary to contract to purchase
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countermeasures that are earlier in the development process than would the other
Senate versions, but not as early as H.R. 2122 would have allowed.
H.R. 2122, S. 1504, and S. 15 as reported by the Senate HELP Committee
specify that countermeasures should be deliverable within five years.  S. 15 as
enacted specifies that countermeasures should be deliverable within eight years.   
HHS Countermeasure Development Program.  H.R. 2122 would have
authorized the HHS Secretary to “initiate and sustain a program that results in the
delivery of priority countermeasures for placement in the stockpile.”  This provision
would have allowed the government to directly develop countermeasures.  This could
be done through several mechanisms including government owned-government
operated (GO-GO) facilities or government owned-contractor operated (GO-CO)
facilities.  This provision was not included in S. 15 as enacted.
Patient Protection during Emergencies.  S. 1504 and S. 15 as enacted
grant the HHS Secretary authority, during a national emergency, to temporarily waive
or modify some patient protection provisions of the Social Security Act and the
Public Health Security and Bioterrorism Preparedness Act of 2002.  These provisions
concern patient privacy and which hospitals patients can be directed to or away from
pursuant to a state emergency plan.  H.R. 2122 and S. 15 as reported by the Senate
HELP Committee lacked this provision.
DHS Terrorism Analyst Hiring.  H.R. 2122 and S. 15 as enacted authorize
appropriations to hire more biological and chemical terrorism analysts in the
Department of Homeland Security’s Directorate for Information Analysis and
Infrastructure Protection (IAIP).  They also authorize appropriations to acquire and
deploy facilities that permit the Undersecretary of IAIP to access all classified
information to which he is entitled.  S. 15 as reported by the Senate HELP
Committee and S. 1504 lacked similar provisions.
Other Differences.  Several other notable differences, including reporting and
recordkeeping requirements, are detailed the tables below.  The italics in the tables
highlight language differences between the bills. 
CRS-7
Table 1.  Short Title
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Short Title Sec. 1 
“Project BioShield Act of
2003.”
Sec. 1 
Same as S. 15 as Reported by
Committee.
Sec. 1
Same as S. 15 as Reported by
Committee
Sec. 1 
“Project BioShield Act of
2004.”
Note: Italics highlight language differences between the bills.
Table 2.  New Health and Human Services Secretary Authorities for 
Countermeasure Research and Development 
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Amends Part B of title IV of
the Public Health Service Act
(PHSA, 42 U.S.C. 284 et




Amends Part B of title III of
the PHSA, (42 U.S.C. 243 et
seq.) by inserting “Sec.






Same as S. 15 as Reported by
Committee.
Sec. 2 
Same as H.R. 2122.
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Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 2 (a) “Sec. 409J (g)”
Defines a qualified
countermeasure as a drug (as
that term is defined by
section 201(g)(1) of the
Federal Food, Drug, and
Cosmetic Act (21 U.S.C.
321(g)(1))), biological
product (as that term is
defined by section 351(i) of
this Act (42 U.S.C. 262(i))),
or device (as that term is
defined by section 201(h) of
the Federal Food, Drug, and
Cosmetic Act (21 U.S.C.
321(h))) that the Secretary
determines to be a priority
(consistent with sections
302(2) and 304(a) of the
Homeland Security Act of
2002) to — 
Sec. 2 (a) “Sec. 319F-1
(a)(2)” and Sec. 2 (e)
Defines qualified
countermeasure as a priority
countermeasure (as defined
in section 319F(h) and as
determined by the Secretary
in accordance with such
section and consistent with
sections 302(2) and 304(a) of




nuclear agent that may cause
a public health emergency
affecting national security.
Sec. 2 (a) “Sec. 409J (g)”
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(a)(2)” and Sec. 2 (d)
Same as S. 15 as Reported by
Committee.
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Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





(A) treat, identify, or prevent
harm from any biological,
chemical, radiological, or
nuclear agent that may cause
a public health emergency
affecting national security; or
(B) treat, identify, or prevent
harm from a condition that
may result in adverse health
consequences or death and
may be caused by
administering a drug,
biological product, or device
that is used as described in
subparagraph (A).
Sec. 2 (e)
Defines a countermeasure as
a drug, biological product,
device, vaccine, vaccine
adjuvant, antiviral, or
diagnostic test that can be
used to — 
(1) to treat, identify, or
prevent infection by a
biological agent or toxin or
harm from any other agent
that may cause a public
health emergency; or 
(2) to treat, identify, or
prevent harm from a
condition that may result in
adverse health consequences
or death and may be caused
by the administering of a
countermeasure described in
(1).
Sec. 2 (a) “Sec. 409J (g)”  
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as H.R. 2122.
Sec. 2 (d)
Same as H.R. 2122.
Same as H.R. 2122.
Same as H.R. 2122.
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Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Lead
Institute
Sec. 2 (a) “Sec. 409J (a)(2)” 
The Director of the National
Institutes of Health (NIH)
shall carry out these
authorities.  The National
Institute of Allergy and
Infectious Diseases (NIAID)
shall be the lead institute




The NIH Director may
delegate to the NIAID
Director authorities as are
necessary to carry out this
function.  The HHS Secretary
may authorize the NIH
Director to work through any
national research institute.  
No similar provision. Sec. 2 (a) “Sec. 409J (a)(2)” 





Sec. 2 (a) “Sec. 409J (a)(3)” 
Authorizes the HHS
Secretary to enter into
interagency agreements for
countermeasure research and
development and to use other
HHS agencies.
Sec. 2 (a) “Sec. 319F-1
(a)(3)” 
Authorizes the HHS




Sec. 2 (a) “Sec. 409J (a)(3)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(a)(3)” 
Same as H.R. 2122.
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Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 2 (a) “Sec. 409J
(a)(2)(D)” 





use of facilities by the
Secretary.
Sec. 2 (a) “Sec. 319F-1
(a)(4)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 409J
(a)(2)(D)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(a)(4)” 




No similar provision. Sec. 2 (a) “Sec. 319F-1
(a)(5)” 
Each award agreement must
state that any products
developed with BioShield
funding must comply with
export-related controls.
No similar provision. Sec. 2 (a) “Sec. 319F-1
(a)(5)” 
Same as H.R. 2122.
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Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 2 (a) “Sec. 409J (b)(1)”
(A) Procurements less than
$25 million for property or







controls shall be developed
for the use of this authority.
Sec. (a) “Sec. 319F-1 (b)(1)” 
(A) Same as S. 15 as
Reported by Committee.
(B) These purchases must
comply with laws and
regulations relating to
contract work hours and
safety standards, examination
of contractor records, and the
Anti-Kickback Act (21 U. S.
C. 57(a) and (b).
(C) Same as S. 15 as
Reported by Committee.
Sec. 2 (a) “Sec. 409J (b)(1)”
(A) Same as S. 15 as
Reported by Committee.
(B) These purchases must
comply with laws and
regulations relating to
contract work hours and
safety standards, examination
of contractor records, the







(C) Same as S. 15 as
Reported by Committee.
Sec. (a) “Sec. 319F-1 (b)(1)”
(A) Same as S. 15 as
Reported by Committee.
(B)These purchases must
comply with laws and
regulations relating to
contract work hours and
safety standards, examination
of contractor records, the
Anti-Kickback Act, bonds of
contractors of public
buildings, middlemen fees
solid waste disposal, and
veterans’ employment
reporting requirements.







Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. (a) “Sec. 409J (b)(2)” 
Authorizes the use of “other
than competitive procedures”
in awarding contracts if that
which is being procured is
available from a limited
number of responsible
sources and no other type of
property or services will
meet the need.
Sec. 2 (a) “Sec. 319F-1
(b)(2)”  
Authorizes the use of “other
than competitive procedures”
in awarding contracts if that
which is being procured is
available from a limited
number of responsible
sources.
Sec. (a) “Sec. 409J (b)(2)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(b)(2)”
Same as H.R. 2122.
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Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






No similar provision. Sec. 2 (a) “Sec. 319F-1
(b)(2)(C)”
Awards must comply with
government-wide
regulations, including
requirements that offers be
solicited from as many
potential sources as is
practicable under the
circumstances, that required
notices be published, and that
submitted offers be
considered.
No similar provision. Sec. 2 (a) “Sec. 319F-1
(b)(2)(C)” 
Awards must comply with
government-wide regulations
(including requirements that
offers be solicited from as
many potential sources as is
practicable under the
circumstances, that required




procurements for which an
agency has authority to use
procedures other than
competitive procedures when
the property or services
needed by the agency are
available from only one
responsible source or only
from a limited number of
responsible sources and no
other type of property or
services will satisfy the needs
of the agency.
CRS-15
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 2 (a) “Sec. 409J (b)(3)”
Procurements less than
$15,000 for property or





internal controls shall be
developed for the use of this
authority.  Government
purchase card preferences do
not apply to these purchases
if they are greater than
$2,500.
Sec. 2 (a) “Sec. 319F-1
(b)(3)”
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 409J (b)(3)”
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(b)(3)”









Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






No similar provision. Sec. 2 (a) “Sec. 319F-1
(b)(4)” 
Notwithstanding any other
provision of law, contracting
agency decisions relating to
countermeasure research and
development procurement
can be reviewed by filing a
protest with the contracting
agency or the Comptroller
General.  If there is a written
finding that a review-related
delay would harm the United
States, the decision to make
the award or procurement is
committed to agency
discretion.  
No similar provision. Sec. 2 (a) “Sec. 319F-1
(b)(4)” 
Notwithstanding 28
U.S.C.18(f), 28 U.S.C. 1491





can be reviewed by filing a
protest with the contracting
agency or the Comptroller
General.  If there is a written
finding that a review-related
delay would harm the United
States, the decision to make




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Expedited
Peer Review
Sec. (a) “Sec. 409J (c)” 
Allows the HHS Secretary to
use an expedited award
process, rather than the
normal peer review process,
for grants, contracts, and
cooperative agreements less
than $1.5 million related to
biomedical countermeasure
R&D activity, if the
Secretary deems there is a
pressing need for an
expedited award. 
No similar provision.
Sec. 2 (a) “Sec. 319F-1
(c)(1)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(c)(2)”
Determination of whether to
employ expedited peer
review with respect to
subsequent awards shall be
determined without regard to
the peer review procedures
used for any prior peer
review of that same award.
Sec. (a) “Sec. 409J (c)”
Same as S. 15 as Reported by
Committee.
No similar provision.
Sec. 2 (a) “Sec. 319F-1
(c)(1)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(c)(2)”
Same as H.R. 2122.
CRS-18
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Agency
Facilities
Sec. 2(a) “Sec. 409J (d)”





facilities and equipment, and
other real or personal
property as the Secretary






No similar provision. Sec. 2(a) “Sec. 409J (d)”




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 2 (a) “Sec. 409J (e)(1)” 
Authorizes the HHS
Secretary to enter into
personal services contracts
with up to 30 experts or
consultants with no limit on
period of service.  
No similar provision.
Sec. 2 (a) “Sec. 409J (e)(2)” 
These contractors are treated
as employees of HHS for
Federal Tort Claims Act
purposes.  
Sec. 2 (a) “Sec. 409J (e)(3)” 
Internal controls for this
authority will be
implemented.
Sec. 2 (a) “Sec. 319F-1 (d)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(d)(1)” 
Pay cannot exceed that of the
U. S. President.  
Sec. 2 (a) “Sec. 319F-1
(d)(2)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(d)(3)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 409J (e)(1)”
Same as S. 15 as Reported by
Committee.
No similar provision.
Sec. 2 (a) “Sec. 409J (e)(2)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 409J (e)(3)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1 (d)”
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(d)(1)” 
Same as H.R. 2122.
Sec. 2 (a) “Sec. 319F-1
(d)(2)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(d)(3)” 
Same as S. 15 as Reported by
Committee.
CRS-20
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 2 (a) “Sec. 409J
(e)(2)(C)” 
The United States has the
right to sue these contractors
to recover payments (and
litigation costs) made to any
claimant stemming from the
job-related gross misconduct
of these contractors.  The
venue for this action will be
in the district court of the
United States in which such
contractor resides or has its
principal place of business.
No similar provision. Sec. 2 (a) “Sec. 409J
(e)(2)(C)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(d)(2)(C)” 





Sec. 2 (a) “Sec. 409J (f)” 
The HHS Secretary may
appoint up to 30 professional
and technical employees to
help NIH respond to pressing
qualified countermeasure
research and development
needs without regard to
provisions governing
appointments in the
competitive service or pay
rates.   
Sec. 2 (a) “Sec. 319F-1 (e)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 409J (f)(1)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(e)(1)”
Same as S. 15 as Reported by
Committee.
CRS-21
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










Sec. 2 (a) “Sec. 409J (f)(2)” 
Provisions in U.S.C. title 5
relating to merit system
principles, prohibited
personnel practices and
preference eligibility apply to
these appointments. 
Sec. 2 (a) “Sec. 319F-1
(e)(2)”
(A) Recruitment and
appointments must be based
solely on the individual’s
abilities, knowledge, and
skills. 























Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 2 (a) “Sec. 409J (f)(2)”
Internal controls for this
authority will be
implemented.
Sec. 2 (a) “Sec. 319F-1
(e)(2)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 409J (f)(3)”
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(e)(3)






Sec. 2 (a) “Sec. 409J (h)” 
All actions by the HHS
Secretary under the authority
of this section are committed
to agency discretion.
Sec. 2 (a) “Sec. 319F-1 (f)”
All actions by the HHS
Secretary under the authority
of this section are committed
to agency discretion, except
those deemed reviewable
under Sec. 319F-1 (b)(4).
Sec. 2 (a) “Sec. 409J (h)” 
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1 (f)”
Same as S. 15 as Reported by
Committee.
CRS-23
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Technical
Amendment
Sec. 2 (b).  
(1) Amends the PHSA (42
U.S.C. 287a-2) to allow the
Director of NIH to work
through the Director of
NIAID to fund public or
nonprofit entities to expand,
remodel, renovate or alter
existing research facilities or
construct new research
facilities.  Increases the
federal share from 50% to
75% for NIAID funded
projects and from 40% to
75% of costs associated with
NIAID use for multipurpose
facilities.  
No similar provision.
Sec. 2 (b).  
(1) Same as S. 15 as
Reported by Committee.
(2) Authorizes such sums as
may be necessary for FY2003
and FY2004 to fund these
improvements.
Sec. 2 (b).  
Same as S. 15 as Reported by
Committee.
No similar provision.
Sec. 2 (b).  
(1) Same as S. 15 as
Reported by Committee.
(2) Authorizes such sums as
may be necessary for FY2004
and FY2005 to fund these
improvements.
CRS-24
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






No similar provision. Sec. 2 (c) 
The HHS Secretary may
initiate and sustain a program
that results in the delivery of
priority countermeasures for
placement in the Strategic
National Stockpile (SNS).
Authorizes the appropriation
of such sums as may be
necessary for each of the
fiscal years 2004 through
2013.  




No similar provision. Sec. 2 (d)
Authorizes the appropriation
of such sums as may be
necessary for each of the
fiscal years 2004 through
2013 for the National
Vaccine Program.
No similar provision. No similar provision.
Technical
Amendment
No similar provision. Sec. 2 (e) 
Amends the PHSA to add the
Secretary of Homeland
Security to the working
group on the preparedness,
prevention, and response to 
bioterrorism and other public
health emergencies.  
No similar provision. Sec. 2 (d)
Same as H.R. 2122.
CRS-25
Table 3.  Biomedical Countermeasures Procurement
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Sec. 3 
Amends PHSA by adding
Sec. 319A-1.
Sec. 3 
Amends PHSA by adding
Sec. 319F-2.
Sec. 3 
Same as S. 15 as Reported by
Committee.
Sec. 3






No similar provision. Sec. 3 (a)
Transfers and amends the
section of the Public Health
Security and Bioterrorism
Preparedness and Response
Act of 2002 (P.L. 107-188,
42 U.S.C. 300hh-12) dealing
with the Strategic National
Stockpile (SNS, Sec. 121) to
the Public Health Services
Act as section 319F-2.
No similar provision. Sec. 3 (a)
Same as H.R. 2122.
CRS-26
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 













Secretary and VA Secretary
shall maintain the Strategic
National Stockpile.
In managing the Stockpile
DHS Secretary shall:
(A) consult with the Working
Group on Bioterrorism





and for the physical security
of the stockpile; 
(C) take into consideration
the timing and location of










Secretary shall maintain the
Strategic National Stockpile. 
Same as H.R. 2122.
Same as H.R. 2122. 
Same as H.R. 2122.








Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 







(D) review and revise, the
contents of the stockpile on a





(E) devise plans for the
effective and timely supply-
chain management of the
stockpile, in consultation
with appropriate Federal,
State and local agencies, and




Same as H.R. 2122.
Same as H.R. 2122.
CRS-28
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 















(F) deploy the stockpile as
required by the Secretary of
Homeland Security to
respond to an actual or
potential emergency; 
(G) deploy the stockpile at
the discretion of the
Secretary to respond to an
actual or potential public
health emergency or other
situation in which
deployment is necessary to
protect the public health or
safety; and




No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(1)(A)”
The special reserve fund
defined in Sec. 319F-2




No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(1)(A)”
Same as H.R. 2122.
CRS-29
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 













for use against a CBRN agent
identified as a material threat
that is approved or cleared by
the Food and Drug
Administration (FDA) or a
biological product licensed
by the HHS Secretary under
42 U.S.C. 262,
or is a priority








for approval or licensing
within five years.
Sec. 3 (a) “Sec. 319F-2
(c)(1)(B)”
Defines a security
countermeasure as a priority
countermeasure against a
CBRN agent identified as a
material threat, that is
determined to be a necessary
countermeasure under 391F-
2(c)(2)(B), and is approved
or cleared by the Food and
Drug Administration (FDA)
or a biological product
licensed by the HHS
Secretary under 42 U.S.C.
262,
or is a priority








for approval or licensing in
the future,
Sec. 3 (a) “Sec. 319A-1
(h)(1)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(1)(B)”
Defines a security
countermeasure as a drug,
biological product, or device 
countermeasure against a
CBRN agent identified as a
material threat, that is
determined to be a necessary
countermeasure under 391F-
2(B)(ii), and is approved or
cleared by the Food and Drug
Administration (FDA) or a
biological product licensed
by the HHS Secretary under
42 U.S.C. 262,
or is a countermeasure for
which the HHS Secretary
determines that sufficient and
satisfactory clinical

















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










No similar provision. or is authorized for
emergency use by the HHS
Secretary.





Sec. 3 “Sec. 319A-1 (a)(1)”
Requires the DHS Secretary
to determine, on an ongoing
basis, which CBRN agents
pose a material risk of use
against the U.S. population. 
Sec. 3 (a) “Sec. 319F-2
(c)(2)(A)”
Requires the DHS Secretary
to determine, on an ongoing
basis, which CBRN agents
pose a material threat. 
Sec. 3 “Sec. 319A-1 (a)(1)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(2)(A)”






Sec. 3 “Sec. 319A-1
(a)(2)(A)”
Requires the HHS Secretary,
in consultation with the DHS
Secretary, to determine the
public health consequences
of use of any of the agents
identified by the DHS
Secretary to pose a material
threat, and to determine the
agents for which priority
countermeasures are
necessary to protect the
public health from a material
threat.
Sec. 3 (a) “Sec. 319F-2
(c)(2)(B)” 
Requires the HHS Secretary
to determine the public
health consequences of use
of any of the agents
identified by the DHS
Secretary to pose a material
threat, and to determine the
agents for which priority
countermeasures are
necessary to protect the
public health from a material
threat.
Sec. 3 “Sec. 319A-1
(a)(2)(A)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(2)(B)” 
Same as H.R. 2122.
CRS-31
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Notification
to Congress
No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(2)(C)”
The DHS and HHS
Secretaries will notify
Congress when any material
threat, public health impact,
or necessary countermeasure
determination is made.  Such
notice shall be in unclassified
or, if necessary classified
form.
No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(2)(C)”
The DHS and HHS
Secretaries will notify
Congress when any material







No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(2)(D)” 
All information to which the
DHS Secretary is entitled,
regardless of classification
level, will be used in making
material threat
determinations.
No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(2)(D)” 








Sec. 3 “Sec. 319A-1 (b)”
The HHS Secretary, in
consultation with the DHS





Sec. 3 (a) “Sec. 319F-2
(c)(3)” 
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (b)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(3)” 
Same as S. 15 as Reported by
Committee.
CRS-32
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 3 “Sec. 319A-1 (c)(1)”
If a countermeasure is found
appropriate but not available,
the DHS and HHS
Secretaries may jointly
submit, for presidential




the procurement of the first
developed appropriate
countermeasure.
Sec. 3 (a) “Sec. 319F-2
(c)(4)(A)” 
If a countermeasure is found
appropriate but not available
or available but cleared only
for alternative purposes, the
DHS and HHS Secretaries
may jointly submit, for
presidential approval, a call
for the development of such
countermeasure and a
commitment to recommend
the procurement of the first
developed appropriate
countermeasure, using the
fund created by Sec. 319-
F(c)(10).
Sec. 3 “Sec. 319A-1 (c)(1)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(4)(A)” 
Same as H.R. 2122.
CRS-33
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 3 “Sec. 319A-1 (b)(2)”
The HHS and DHS
Secretaries will, to the extent
practicable, include in the
proposal the estimated
quantity and price of the
future purchase, necessary
measures of minimum safety
and effectiveness, and any
other information necessary
to encourage and facilitate
research, development, and
manufacture of the
countermeasure or to provide
specifications for it.
Sec. 3 (a) “Sec. 319F-2
(c)(4)(B)” 
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (b)(2)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(4)(B)” 
Same as S. 15 as Reported by
Committee.
CRS-34
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 3 “Sec. 319A-1 (c)(3)”
If the President approves a
proposal the DHS and HHS
Secretaries shall make known
to persons who may respond
to a call for the
countermeasure involved — 
the call for the
countermeasure;
the required specifications
for the countermeasure; and 
 
a commitment for a
recommendation for
procurement of the first such
specific countermeasure that
meets the conditions for
procurement under
subsection (d) and the
specifications under Sec. 3
“Sec. 319A-1 (d)(2)” 
[see below]
Sec. 3 (a) “Sec. 319F-2
(c)(4)(C)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
the commitment described in
Sec. 3 (a) “Sec. 319F-2
(c)(4)(A)” 
[see above]
Sec. 3 “Sec. 319A-1 (c)(3)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(4)(C)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as H.R. 2122.
CRS-35
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








Sec. 3 “Sec. 319A-1 (d)(1)”
The HHS Secretary, in
consultation with the DHS




specified in Sec. 319A-1 (i).
Sec. 3 (a) “Sec. 319F-2
(c)(5)(A)” 
The HHS Secretary, in
consultation with the DHS
Secretary, will determine if
specific countermeasures are
appropriate for procurement
using the special reserve
fund defined in Sec. 319F-2
(c)(10).
Sec. 3 “Sec. 319A-1 (d)(1)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(5)(A)” 
Same as H.R. 2122.
CRS-36
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 











qualify for this funding the
HHS Secretary must
determine:
(B)(i) quantities of the
product that will be needed 
for the SNS,
(B)(ii) feasibility of delivery
of sufficient quantities within
five years, and
(C) that there is no
significant commercial
market for the product, at the
time of this determination,
other than as a
countermeasure.  This must
be annually redetermined.
Sec. 319F-2 (c)(5)(B).
In making this determination
the HHS Secretary will
determine and consider:
(i) Same as S. 15 as Reported
by Committee.
(iii) Same as S. 15 as
Reported by Committee. 
(iii) whether there is a lack of
a significant commercial
market for the product at
time of procurement other
than as a countermeasure.
Sec. 319A-1 (d)(2).
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(5)(B)”
Same as H.R. 2122.
(i) Same as S. 15 as Reported
by Committee.
(ii) feasibility of delivery of
sufficient quantities within
eight years, and





















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 3. “Sec. 319A-1 (e)”
(1) If a countermeasure is
deemed appropriate, the HHS
and DHS Secretaries, in
coordination with the
Director of Office of
Management and Budget,
will submit to the President a
proposal to procure the
countermeasure.




Sec. 3 (a) “Sec. 319F-2
(c)(6)”
(A) If a countermeasure is
deemed appropriate, the HHS
and DHS Secretaries, in
coordination with the
Director of Office of
Management and Budget,
will submit to the President a
proposal to procure the
countermeasure using the
special reserve fund defined
in Sec. 319F-2 (c)(10).  
(B) Same as S. 15 as
Reported by Committee.
Sec. 3. “Sec. 319A-1 (e)”
Same as S.15 as Reported by
Committee.
Same as S.15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(6)”
Same as S.15 as Reported by
Committee.
Same as S.15 as Reported by
Committee.
CRS-38
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Notice to
Congress
Sec. 3 “Sec. 319A-1 (e)(3)”
The DHS Secretary will
notify Congress of each
presidential decision to




Sec. 3 (a) “Sec. 319F-2
(c)(6)(C)” 





approve the use of the special
reserve fund. This notice will
include:
an explanation of the
decision to use the special
reserve fund, the potential
countermeasure supplier or
suppliers (when available),
and whether other potential
suppliers were considered
and reasons for any rejection
of them.
Sec. 3 “Sec. 319A-1 (e)(3)”
Same as S.15 as Reported by
Committee.
No similar provision.
Sec. 3 (a) “Sec. 319F-2
(c)(6)(C)” 
Same as H.R. 2122.
Same as H.R. 2122.
CRS-39
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 3 “Sec. 319A-1 (c)(4)”
Countermeasures developed
after a procurement can also








Sec. 3 (a) “Sec. 319F-2
(c)(6)(D)” 
Same as S.15 as Reported by
Committee.
Determination of an
improvement is committed to
agency discretion.
Sec. 3 “Sec. 319A-1 (c)(4)”
Same as S.15 as Reported by
Committee.
No similar provision.
Sec. 3 (a) “Sec. 319F-2
(c)(6)(D)” 
Same as S.15 as Reported by
Committee.




No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(6)(E)” 
Recommendations and
approvals under Sec. 319F-2
(c)(6) are to the
determination that the special
reserve fund will be used for
a procurement; not to the
substance of contracts nor
other matters relating to
awards.
No similar provision. Sec. 3 (a) “Sec. 319F-2
(c)(6)(E)”  
Same as H.R. 2122.
CRS-40
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 3 “Sec. 319A-1
(i)(2)(C)”
Funds appropriated under
this subsection cannot be
used for administrative costs.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(A)-(B)” 
The DHS Secretary will
reimburse the HHS Secretary
for all costs of presidentially
approved countermeasure
procurements. 
However, the special reserve




Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(A)-(B)”
Same as H.R. 2122.
Same as H.R. 2122.
Procure-
ment 
Sec. 3 “Sec. 319A-1 (f)(1)”
The HHS Secretary is





price), and entering into,
contracts and cooperative
agreements, and for carrying
out such other activities as
may reasonably be required.
The HHS Secretary will
promulgate any regulations
necessary to implement these
procurement provisions.
Sec 3 (a) “Sec. 319F-2
(c)(7)(C)(i)” 
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (f)(1)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec 3 (a) “Sec. 319F-2
(c)(7)(C)(i)” 
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
CRS-41
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Contract
Terms
Sec. 3 “Sec. 319A-1 (f)(2)”
The procurement contracts
will include the following
terms:
Payment conditioned on
delivery of a substantial
portion of the number of
contracted units. 
No similar provision.
The contract period cannot
be longer than five years. 
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(ii)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Up to a 10% advance
payment to ensure success of
a project can be made at the
discretion of HHS Secretary. 
This advance payment must
be refunded if the contractor
fails to perform under the
terms of the contract except
in special circumstances as
determined by the Secretary. 
The contract period cannot
be longer than five years, or
up to eight years if the HHS
Secretary determines at the
time of initial award that a
longer period is justified. 
Sec. 3 “Sec. 319A-1 (f)(2)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
No similar provision.
Same as S. 15 as Reported by
Committee.
Sec 3 (a) “Sec. 319F-2
(c)(7)(C)(ii)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Up to a 10% advance
payment to ensure success of
a project can be made at the
discretion of HHS Secretary. 
This advance payment must
be refunded if the contractor
fails to perform under the
terms of the contract.
Same as H.R. 2122.
CRS-42
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Contracts may be renewed
for additional periods of up
to five years each.
 No similar provisions.
The vendor must seek
approval, clearance or
licensing of product.  The
HHS Secretary may waive
this provision.
Same as S. 15 as Reported by
Committee.
The vendor must comply
with all applicable export-
related controls.
No similar provisions.
Same as S. 15 as Reported by
Committee.
No similar provisions.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as H.R. 2122.
Same as S. 15 as Reported by
Committee.
CRS-43
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




The contract may specify: 
That the vendor must store
the countermeasure.  In this
case the special fund can be
used to pay the vendor for
the costs of shipping,
handling, storage and related
costs of the countermeasure
a discounted price for a
product that has not been
licensed or approved at the
time of delivery, and
that the HHS Secretary may
terminate the contract for the
failure to deliver a reasonable
number (as determined by
the Secretary) of units of
product by three years after
the contract commenced.
The contract may specify: 
Same as S. 15 as Reported by
Committee.
 No similar provision.
No similar provision.
The contract may specify: 
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
The contract may specify: 
Same as S. 15 as Reported by
Committee.




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 3 “Sec. 319A-1 (f)(3)”
Simplified acquisition






Sec. 3 (a)  “Sec. 319F-2
(c)(7)(C)(iii)(I)”
Simplified acquisition
procedures will apply to
countermeasure
procurements for which the
HHS Secretary determines
that there is pressing need.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(iii)(II)”
These purchases must
comply with laws and
regulations relating to
contract work hours and
safety standards, examination
of contractor records, and the
Anti-Kickback Act.  
No similar provision.
Sec. 3 “Sec. 319A-1 (f)(3)”
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1
(f)(3)(B)”
These purchases must
comply with laws and
regulations relating to
contract work hours and
safety standards, examination
of contractor records, the








Sec 3 (a) “Sec. 319F-2
(c)(7)(C)(iii)(I)”
Same as H.R. 2122.
Sec. 3 (a)  “Sec. 319F-2
(c)(7)(C)(iii)(II)”
These purchases must
comply with laws and
regulations relating to
contract work hours and
safety standards, examination
of contractor records, the
Anti-Kickback Act, bonds of
contractors of public
buildings, middlemen fees,
the Solid Waste Disposal Act,
and veterans’ employment
reporting requirements.
Sec 3 (a) “Sec. 319F-2
(c)(7)(C)(iii)(III)”
The Secretary shall establish
appropriate internal controls
for procurements under this
clause.
CRS-45
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




No similar provision. No similar provision. No similar provision. Sec. 3 (a) “”Sec. 319F-2
(c)(7)(C)(iii)(IV)” 
If the Secretary determines
that the mission of the
BioShield Program under the
Project BioShield Act of
2004 would be seriously
impaired by fair and open
competition, the Secretary
may conduct a procurement








Sec. 3 “Sec. 319A-1 (f)(4)”
Authorizes the use of
noncompetitive procedures to
procure a product available
from a limited number of
responsible sources.  
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(iv)”
Authorizes the use of other
than competitive procedures
to procure a product
available from a limited
number of responsible
sources.  
Sec. 3 “Sec. 319A-1 (f)(4)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(iv)”
Same as H.R. 2122.
CRS-46
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








No similar provision. The Secretary shall




offers be solicited from as
many potential sources as is
practicable under the
circumstances, that required
notices be published, and that
submitted offers be
considered.
No similar provision. The Secretary shall




offers be solicited from as
many potential sources as is
practicable under the
circumstances, that required




procurements for which an
agency has authority to use
procedures other than
competitive procedures when
the property or services
needed by the agency are
available from only one
responsible source or only
from a limited number of
responsible sources and no
other type of property or
services will satisfy the needs
of the agency.
CRS-47
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 3 “Sec. 319A-1 (f)(5)”
The HHS Secretary may
enter into contracts for a
single countermeasure with
more than one vendor.  In
these cases contracts may be
constructed to award a
greater share of the
procurement to the first
vendor to successfully meet
the terms of the contract.
Determinations of the
success of meeting all of the
requirements by the HHS
Secretary are committed to
agency discretion.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(v)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (f)(5)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(v)”
Same as S. 15 as Reported by
Committee.









Sec. 3 “Sec. 319A-1 (f)(6)”
A decision by the HHS
Secretary to extend the
closing date for receipt of
proposals for a procurement
is committed to agency
discretion.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(vi)”
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (f)(6)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(vi)”
Same as S. 15 as Reported by
Committee.
CRS-48
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








Sec. 3 “Sec. 319A-1 (f)(7)”
The HHS Secretary may
stipulate that all potential
sources must provide, on
request, information that
would allow the HHS to  use
advance procurement
planning or market research. 
Vendors who do not provide
such information can be
excluded from consideration.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(vii)” 
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (f)(7)”
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(7)(C)(vii)” 




Sec. 3 “Sec. 319A-1 (g)”
HHS and DHS Secretaries
may enter into interagency
agreements with other
federal agencies to facilitate
procuring these
countermeasures. 
Only the DHS and HHS
Secretaries may exercise the
authorities provided by this
section.
Sec. 3 (a) “Sec. 319F-2
(c)(8)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 “Sec. 319A-1 (g)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(8)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
CRS-49
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 3 “Sec. 319A-1 (i)(2)”
Amounts appropriated under




entered into before January
1, 2003, or
(B) new contracts or
obligations for procuring a
countermeasure after a
determination that it has
significant commercial
market other than as a
countermeasure and; 
(C) administrative costs.
Sec. 3 (a) “Sec. 319F-2
(c)(9)”
The special reserve fund
cannot be used to pay for:
(A) vaccines under
procurement contracts
entered into before the
enactment of this Act or
No similar provision.
(B) Same as S. 15 as
Reported by Committee.
Sec. 3 “Sec. 319A-1 (i)(2)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 3 (a) “Sec. 319F-2
(c)(9)”
Same as H.R. 2122.
Same as H.R. 2122.
No similar provision.
(B) costs other than
payments made by the
Secretary to a vendor for a




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Definitions No similar provision.
No similar provision.
Sec. 3 (a) “Sec. 319F-2
(c)(10)(A)”
Special reserve fund in this
section has the same meaning
as special reserve fund in
Sec. 510 of the Homeland
Security Act of 2002 (6




In the House of
Representatives: the




Reform, and the Select
Committee on Homeland
Security (or any successor to
the Select Committee).
In the Senate: the Committee
on Health, Education, Labor,
and Pensions, the Committee





Sec. 3 (a) “Sec. 319F-2
(c)(10)(A)”




 Same as H.R. 2122.
In the Senate: the
appropriate committees.
CRS-51
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Definitions
(continued)
Sec. 3 “Sec. 319A-1 (h)(2)”
Defines biomedical
countermeasure as a drug,
biological product, or device
used:
(1) to treat, identify, or
prevent harm from any
CBRN agent that may cause
a public health emergency
affecting national security; or 
(2) to treat, identify, or
prevent harm from a
condition that may result in
adverse health consequences
or death and may be caused




The PHSA, as modified by
this legislation, defines a
countermeasure as a drug,
biological product, device,
vaccine, vaccine adjuvant,
antiviral, or diagnostic test
that can be used
(1) to treat, identify, or
prevent infection by a
biological agent or toxin or
harm from any other agent
that may cause a public
health emergency; or 
(2) Same as S. 15 as
Reported by Committee.
Sec. 3 “Sec. 319A-1 (h)(2)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 2 (a) “Sec. 319F-1
(a)(2)” and Sec. 2 (d)
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
CRS-52
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








required by the transfer of
the SNS from the Public
Health Security and
Bioterrorism Preparedness
and Response Act of 2002 to
the PHSA. 
No similar provision. Sec. 3 (a) “Sec. 319F-2 (d-
f)”





No similar provision. Sec. 3 (b)
No similar provision.
Adds to the Homeland
Security Act of 2002 (P.L.
107-296, 6 U.S.C. 311 et
seq.) “Sec. 510 Procurement
of Security Countermeasures
for the Strategic National
Stockpile.”
No similar provision. Sec. 3 (b)
(1) Amends Homeland
Security Act (P.L. 107-296)
to be consistent with the
transfer of the Strategic
National Stockpile to the
direct control of the HHS
Secretary.
Same as H.R. 2122.
CRS-53
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 3 “Sec. 319A-1 (i)”
Appropriates, out of any
moneys in the Treasury not
otherwise appropriated, for
FY2003 and for each fiscal
year thereafter, such sums as
may be necessary for the
costs incurred by the HHS
Secretary in the procurement
of presidentially approved
countermeasures.
Sec. 3 (b) “Sec. 510 (a)”
Authorizes the appropriation




Of this total, not more than
$3.418 billion may be
obligated for FY2004-2008
and not more than $890
million for FY2004.  This
money goes into the special
reserve fund as defined in
Sec. 510 (b).
Sec. 3 “Sec. 319A-1 (i)”
Authorizes the appropriation




Of this total, not more than
$3.418 billion may be
authorized for FY2004-2008
and not more than $890
million for FY2004.
Sec. 3 (b) “Sec. 510 (a)”
Same as H.R. 2122.






















No similar provision. Sec. 3 (b) “Sec. 510 (b)”
Special reserve fund means
the appropriations account
established as a result of any
appropriations made under
Sec. 510 (a). 
No similar provision. Sec. 3 (b) “Sec. 510 (b)”




any other appropriation made










Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 







Sec. 3 (b) “Sec. 510 (c)”
(1) It is the intent of the
Congress that unobligated
amounts in this fund will not
be applied, through
reprogramming or otherwise,
to any other purpose.
(2)Appropriations to the
special reserve fund are
available to be obligated





Sec. 3 (b) “Sec. 510 (c)”
No similar provision.
Same as H.R. 2122.
CRS-55
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








Sec. 3 (b) “Sec. 510 (d)(1)”
Authorizes the appropriation
of $5 million for FY2003 and
such sums as may be
necessary for FY2004-2006
for the hiring of  Chemical,
Biological, Radiological, and
Nuclear (CBRN)  threat
assessment analysts within




Sec. 3 (b) “Sec. 510 (d)(2)”
Authorizes the appropriation
of such sums as may be
necessary for FY2003-
FY2006 for the acquisition
and deployment of secure
facilities to permit the DHS
Secretary to receive (by the
end of 2003) all classified
information and products to




Sec. 3 (b) “Sec. 510 (d)(1)”
Authorizes the appropriation
of such sums as may be
necessary for FY2004-2006
for the hiring of  CBRN
threat assessment analysts
within the DHS IAIP.
Sec. 3 (b) “Sec. 510 (d)(2)”
Authorizes the appropriation
of such sums as may be
necessary for FY2004-
FY2006 for the acquisition
and deployment of secure
facilities to permit the DHS
Secretary to receive (not
later than 180 days after
enactment) all classified
information and products to
which the Undersecretary for
IAIP is entitled.
CRS-56
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








No similar provision. No similar provision. No similar provision. Sec. 3 (c)
The functions, personnel,
assets, unexpended balances,
and liabilities of the Strategic
National Stockpile are
transferred from the DHS
Secretary to the HHS
Secretary.
Exceptions: Duties of the
DHS Secretary described in
this act and the “Biodefense
Countermeasure” funds
appropriated in the 2004
DHS Appropriations Act
(P.L. 108-90) are not
transferred.
CRS-57
Table 4. Authorization for Medical Products for Use in Emergencies
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Sec. 4 
Authorization for Medical
Products for Use in
Emergencies.  Amends
Subchapter E of chapter V of
the Federal Food, Drug, and
Cosmetic Act (21 U.S.C.
360bbb et seq.) by adding
“Sec. 564. Authorization for
Medical Products for Use in
Emergencies.”
Sec. 4
Same as S. 15 as Reported by
Committee.
Sec. 4  
Same as S. 15 as Reported by
Committee.
Sec. 4









Sec. 4 (a) “Sec. 564 (a)”
The HHS Secretary may
authorize the temporary
introduction into interstate
commerce, of a drug, device,
or biological product
intended for use in an actual
or potential emergency.
Sec. 4 (a) “Sec. 564 (a)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (a)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (a)”
Same as S. 15 as Reported by
Committee.
CRS-58
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




No similar provision. Sec. 4 (a) “Sec. 564 (a)(2)”
The HHS Secretary may
make emergency use
authorizations for products
that are not approved,
licensed, or cleared for
commercial distribution
(unapproved products) and
for products that are
approved for other uses
(unapproved use of an
approved product).
No similar provision. Sec. 4 (a) “Sec. 564 (a)(2)”
Same as H.R. 2122.
Relation to
Other Uses
No similar provision. Sec. 4 (a) “Sec. 564 (a)(3)”
Emergency use
authorizations are in addition
to any other approved uses of
the product.
No similar provision. Sec. 4 (a) “Sec. 564 (a)(3)”
Same as H.R. 2122.
CRS-59
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Definitions No similar provision. Sec. 4 (a) “Sec. 564 (a)(4)”
Biological product has the
meaning given in sec. 351 of
the PHSA.
Emergency use means the
use of a product during an
actual emergency or potential
emergency.
Product means a drug, device
or biological product.
An unapproved product is a
product without approval,
license, or clearance for
commercial distribution.
An unapproved use of an
approved product is the use
of a product that is not
approved for that use but has
been approved for another
use.
No similar provision. Sec. 4 (a) “Sec. 564 (a)(4)”
Same as H.R. 2122.
Same as H.R. 2122.
Same as H.R. 2122.
Same as H.R. 2122.































Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Emergency
Declaration
Sec. 4 (a) “Sec. 564 (b)(1)”
The HHS Secretary may
declare an emergency if:
(A) The Homeland Security
(DHS)  Secretary determines
that there is a  domestic
emergency or significant
potential for one  involving
the heightened risk of attack
with a specified biological,
chemical, radiological or
nuclear (CBRN) agent, or
(B) The Defense Secretary
determines that there is a
military emergency or
significant potential for one
involving the heightened risk
to U.S. military forces of
attack with a CBRN agent, or
Sec. 4 (a) “Sec. 564 (b)(1)”
The HHS Secretary may
declare an emergency if:
(A) The Homeland Security
(DHS)  Secretary determines
that there is a national
emergency or significant
potential for one  involving
the heightened risk of attack
with a specified biological,
chemical, radiological or
nuclear (CBRN) agent, or
(B) The Defense Secretary
determines that there is a
military emergency or
significant potential for one
involving the heightened risk
to U.S. military forces of
attack with a specified CBRN
agent, or
Sec. 4 (a) “Sec. 564 (b)(1)”
The HHS Secretary may
declare an emergency if:
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (b)(1)”
The HHS Secretary may
declare an emergency if:
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
CRS-61
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




(C) the HHS Secretary
determines that there is a
public health emergency
under Section 319 of the
PHSA affecting national
security and involving a
specified CBRN agent, or a
specified disease or condition
that may be attributable to
such agent.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.




Sec. 4 (a) “Sec. 564
(b)(2)(A)”
An emergency declaration
will terminate on the earlier
of:
(i) a determination by the
HHS Secretary, in




declaration no longer exist,
or
(ii) one year from the
declaration date.
Sec. 4 (a) “Sec. 564
(b)(2)(A)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564
(b)(2)(A)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564
(b)(2)(A)”
Same as S. 15 as Reported by
Committee.
CRS-62
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Declaration
Renewal
Sec. 4 (a) “Sec. 564
(b)(2)(B)”
The HHS Secretary may
renew a declaration. 
Renewed declarations will be
subject to termination under
the above conditions and
may also be renewed.
Sec. 4 (a) “Sec. 564
(b)(2)(B)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564
(b)(2)(B)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564
(b)(2)(B)”




No similar provision. No similar provision. No similar provision. Sec. 4 (a) “Sec. 564
(b)(2)(C)”




shall consult with the
manufacturer of such product
with respect to the
appropriate disposition of the
product.
CRS-63
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




No similar provision. Sec. 4 (a) “Sec. 564 (b)(3)”




terminated to allow enough
time to:
(A) allow removal of
unapproved products from
distribution channels and 
(B) allow labeling changes
for products used for
unapproved uses.
No similar provision. Sec. 4 (a) “Sec. 564 (b)(3)”
Same as H.R. 2122.
Publication Sec. 4 (a) “Sec. 564 (b)(3)”
The HHS Secretary must
publish in the Federal





Sec. 4 (a) “Sec. 564 (b)(4)”
The HHS Secretary must
publish in the Federal
Register each declaration,
determination and renewal.
Sec. 4 (a) “Sec. 564 (b)(3)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (b)(4)”
The HHS Secretary must
publish in the Federal
Register each declaration,
determination, advanced














Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 4 “Sec. 564 (c)” 
The HHS Secretary may
authorize the emergency use
of a product only if the 
Secretary concludes — 
(1) that an agent specified in
the emergency declaration
can cause a serious or life-
threatening disease or
condition;
(2) that, based on the totality
of scientific evidence
available to the Secretary, it
is reasonable to believe that 
— 




disease or condition caused
by that agent or by a
countermeasure against that
Sec. 4 “Sec. 564 (c)” 
The HHS Secretary may
authorize the emergency use
of a product only if, after
consultation with the
Director of the National
Institutes of Health and the




Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 “Sec. 564 (c)” 
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 “Sec. 564 (c)” 
Same as H.R. 2122.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
(A) the product may be
effective in diagnosing,
treating, or preventing a life-
threatening disease or
condition caused by that
agent or by a countermeasure
against that agent; and 
CRS-65
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





(B) the known and potential
benefits of the product 
outweigh its known and
potential risks.
(3) that there is no adequate,
approved, and available
alternative to the product for
detecting, diagnosing,
preventing, or treating such
disease or condition; and
(4) that such other criteria as
the Secretary may by
regulation prescribe are
satisfied.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
(3) that there is no adequate,
approved, and available
alternative to the product for
diagnosing, preventing, or
treating such disease or
condition; and
Same as S. 15 as Reported by
Committee.
CRS-66
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 4 “Sec. 564 (d)”
An authorization of a product
under this section shall state
— 
(1) each disease or condition
and the intended use of the






effectiveness of the product
in detecting, diagnosing,
preventing, or treating such
diseases or conditions,




Same as S. 15 as Reported by
Committee.
(A) each disease or condition
for which the product may be
used within the scope of the
authorization;
(B) the Secretary’s
conclusions, that the known
and potential benefits of the
product, outweigh the known
and potential risks of the
product; and
(C) Same as S. 15 as
Reported by Committee.
Sec. 4 “Sec. 564 (d)”
Same as S. 15 as Reported by
Committee.
(1)Same as S. 15 as Reported
by Committee.
No similar provision.
(2) Same as S. 15 as
Reported by Committee.
Sec. 4 (a) “Sec. 564 (d)”
Same as S. 15 as Reported by
Committee.
(1) Same as S. 15 as
Reported by Committee.




effectiveness of the product
in diagnosing, preventing, or
treating such diseases or
conditions, including an
assessment of the available
scientific evidence.
CRS-67
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Confidential
Information
No similar provision. Sec. 564 (d)(2).
Nothing in this section alters
or amends 18 U.S.C. 1905 or
5 U.S.C. 552(b)(4).






















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 









Sec. 4 “Sec. 564 (e)”




and the provision of
information) designed to
ensure that —  
(1) to the extent feasible,
ensuring those administering
the countermeasure know
that the Secretary has
authorized the product solely
for emergency use, the
significant known and
potential benefits and risks of
the product (and the extent to
which these are unknown),
and of any available
alternatives and their risks
and benefits.
Sec. 4(a) “Sec. 564
(e)(1)(A)”
With respect to emergency
use of an unapproved
product, the HHS Secretary
will establish authorization
conditions to protect public
health including —  




that the Secretary has
authorized the emergency use
of the product, the significant
known and potential benefits
and risks of the product (and
the extent to which these are
unknown), and of any
available alternatives and
their risks and benefits.
Sec. 4 “Sec. 564 (e)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4(a) “Sec. 564
(e)(1)(A)”
With respect to emergency
use of an unapproved
product, the HHS Secretary
will establish authorization
conditions to protect public
health including — 




the Secretary has authorized
the emergency use of the
product, the significant
known and potential benefits
and risks of the product (and
the extent to which these are
unknown), and of any
available alternatives and
their risks and benefits.
CRS-69
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










(2) to the extent feasible,
(including requirements
concerning product labeling
and the provision of
information) ensuring that
those receiving the product
know — 
that the Secretary has
authorized the product solely
for emergency use, the
significant known and
potential benefits and risks of
the product (and the extent to
which these are unknown), of
any available alternatives and
their risks and benefits, and
of the option to accept or
refuse administration of the
product and any
consequences of doing so;
Sec. 4 “Sec. 564 (e)(8)”
Same as H.R. 2122.
(ii) to the extent feasible,
ensuring that those receiving
the product know — 
that the Secretary has
authorized the emergency use
of the product, the significant
known and potential benefits
and risks of the product (and
the extent to which these are
unknown), of any available
alternatives and their risks
and benefits, and of the
option to accept or refuse
administration of the product
and any consequences of
doing so;
(iii) appropriate conditions
for the monitoring and
reporting of adverse events
associated with use of the
product;
(2) Same as S. 15 as
Reported by Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 “Sec. 564 (e)(8)”
Same as H.R. 2122.
(ii) to the extent practical,
ensuring that those receiving
the product know — 
that the Secretary has
authorized the emergency use
of the product, the significant
known and potential benefits
and risks of the product (and
the extent to which these are
unknown), of any available
alternatives and their risks
and benefits, and of the
option to accept or refuse
administration of the product
and any consequences of
doing so;
(iii) Same as H.R. 2122.
CRS-70
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










Sec. 4 “Sec. 564 (e)(6)”
Requirements concerning
recordkeeping and reporting,
including records access by
the Secretary and publication
of data.
(iv) For manufacturers of the
product, appropriate
conditions concerning record
keeping  and reporting
including records access by
the Secretary.
Sec. 4 “Sec. 564 (e)(6)”
Same as S. 15 as Reported by
Committee.
(iv) Same as H.R. 2122.
CRS-71
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 









Sec. 4 “Sec. 564 (e)”
The HHS Secretary is




necessary to protect public
health including — 
(3) impose limitations on
which entities may distribute
the product for emergency
use and on how distribution
is to be performed;
(4) impose limitations on
who may administer the
product for emergency use,
and on the categories of
individuals to whom, and the
circumstances under which,
the product may be
administered;
Sec. 4 (a) “Sec. 564
(e)(1)(B)”
With respect to emergency
use of an unapproved
product, The HHS Secretary
may establish additional
conditions on authorizations
to protect public health
including — 
(i) on which entities may
distribute the product for
emergency use and on how
distribution is to be
performed;
(ii) on who may administer
the product for emergency
use, and on the categories of
individuals to whom, and the
circumstances under which,
the product may be
administered.;
Sec. 4 “Sec. 564 (e)”
Same as S. 15 as Reported by
Committee.
(3) Same as S. 15 as
Reported by Committee.
(4) Same as H.R. 2122.
Sec. 4 (a) “Sec. 564
(e)(1)(B)”
With respect to the
emergency use of an
unapproved product, the
Secretary may, for a person
who carries out any activity




section as the Secretary finds
necessary or appropriate to
protect the public health,
including the following:
(i) Same as H.R. 2122.
















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 














clinical trials, or other
research needed to support
marketing approval of the
product.
(6) The Secretary shall




including records access by









including records access by
the Secretary with respect to
the emergency  use of the
product.
No similar provision.
(5) Same as S. 15 as
Reported by Committee.
(6) Same as S. 15 as
Reported by Committee.
(iii) Appropriate conditions
with respect to the collection
and analysis of information,
during the period when the
authorization is in effect,
concerning the safety and
effectiveness of the product
with respect to its emergency
use;
No similar provision.


















ments.   
CRS-73
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










(7) The HHS Secretary may




with respect to the product,
of current good
manufacturing practice
otherwise applicable to the
manufacture, processing,
packing, or holding of
products subject to regulation
under this act.
(iv) with respect to the
emergency use of the
product, waive or limit, to
the extent appropriate given




otherwise applicable to the
manufacture, processing,
packing, or holding of these
products subject to regulation
under this act, including such
requirements established in
section 501 of the Federal
Food, Drug, and Cosmetic
Act (FFDCA).
(7) Same as S. 15 as
Reported by Committee.
Sec. 4 (a) “Sec. 564 (e)(3)”








Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 











Sec. 4 (a) “Sec. 564 (e)(2)”
For unapproved use of an
approved product
authorization:
The Secretary may, for
manufacturers of the product
who choose to carry out one
or more activities for which
the authorization is issued,
establish any of the
conditions described in
clauses Sec. 564 (e)(1)(A)(i -
iv)
(i) If the manufacturer of the
product chooses not to make
an authorized change to the
product label to reflect the
emergency authorization, the 
authorization may not allow
the product distributors or
any other person to alter or
obscure the labeling provided





Sec. 4 (a) “Sec. 564 (e)(2)”
Same as H.R. 2122.
For a manufacturer of the
product who carries out any
activity for which the
authorization is issued, the





clauses (i) and (ii) of Sec.
564 (e)(1)(A) (1)(A), and
may establish conditions
described in clauses (iii) and
(iv) of such paragraph.
















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








No similar provision. (ii) In the circumstances
described in clause (i), an
authorization under this
section regarding the
emergency use may, for
persons who do not
manufacture the product and
who choose to act under this
clause, authorize such
persons to provide
information on the product in
addition to the labeling
provided by the
manufacturer, subject to
compliance with clause (i).
Such additional information
shall not be considered
labeling for purposes of
section 502.
No similar provision. (ii) In the circumstances
described in clause (i), for a
person who does not
manufacture the product and
who chooses to act under this
clause, an authorization
under this section regarding
the emergency use shall, to
the extent practicable,
authorize such person to
provide appropriate
information with respect to
such product in addition to
the labeling provided by the
manufacturer, subject to
compliance with clause (i).
While the authorization
under this section is effective,
such additional information
shall not be considered
labeling for purposes of
section 502.
CRS-76
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








No similar provision. No similar provision. No similar provision. Sec. 4 (a) “Sec. 564 (e)(4)”




that relate to the emergency
use of a product for which an
authorization under this
section is issued (whether an
unapproved product or an







Sec. 4 “Sec. 564 (f)”
Emergency authorizations
will continue until the earlier
of a termination of the
emergency declaration or a
revocation of emergency use
authorization by the HHS
Secretary under Sec. 564 (g).
After authorization
terminates, patients already
receiving the product may
continue to do so for as long
as is deemed necessary by
the patients’ attending
physicians.
Sec. 4 “Sec. 564 (f)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 “Sec. 564 (f)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 “Sec. 564 (f)”




receiving the product may
continue to do so for as long




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 4 (a) “Sec. 564 (g)”






The HHS Secretary may
revoke an authorization if the
authorization criteria under
Sec. 564 (c) are no longer
met or other circumstances
make such a revocation
appropriate.  
This decision is not
reviewable.
Sec. 4 (a) “Sec. 564 (g)”
Same as S. 15 as Reported by
Committee.
The HHS Secretary may
revoke an authorization if the
authorization criteria under
Sec. 564 (c) are no longer
met.  
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (g)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (g)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
CRS-78
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Publication Sec. 4 (a) “Sec. 564 (h)”
The HHS Secretary will
promptly publish in the
Federal Register, and provide
to the appropriate
congressional committees, a




Sec. 4 (a) “Sec. 564 (h)”
The Secretary shall promptly
publish in the Federal
Register a notice of each
authorization, and each
termination or revocation of
an authorization, and an
explanation of the reasons
therefor, under this section.
No similar provision.
Sec. 4 (a) “Sec. 564 (h)”
Same as S. 15 as Reported by
Committee.
No similar provision.
Sec. 4 (a) “Sec. 564 (h)”
The Secretary shall promptly
publish in the Federal
Register a notice of each
authorization, and each
termination or revocation of
an authorization under this
section, and an explanation
of the reasons therefor
(which may include a
summary of data or
information that has been
submitted to the Secretary in
an application under section
505(i) or section 520(g), even




Nothing in this section alters
or amends section 1905 of
title 18, United States Code,















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Record-
keeping
Sec. 4 (a) “Sec. 564 (i)(1)” 
The HHS Secretary may
require persons, including a




prescribes, or administers a
product that is the subject of
such an authorization, to
establish and maintain — 
data that is obtained from
such activity and that
pertains to the effectiveness
or safety of such product;
such records as are necessary
to determine, or facilitate a
determination, whether there
may be any violation of this
section or of a regulation
promulgated under this
section; and







Sec. 4 (a) “Sec. 564 (i)(1)” 
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.







Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 4 (a) “Sec. 564 (i)(2)” 
The HHS Secretary may
require a person who holds
an authorization under this
section, or who
manufactures, distributes,
prescribes, or administers a
product that is the subject of
such an authorization, to
provide to the Secretary all
data that is obtained from
such activity and that
pertains to the safety or
effectiveness of such
product.
Every person required under
this section to establish or
maintain records, and every
person in charge or custody
of such records, shall, upon
request by the Secretary,
permit the Secretary at all
reasonable times to have




Sec. 4 (a) “Sec. 564 (i)(2)” 
Same as S. 15 as Reported by
Committee.





Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 4 (a) “Sec. 564 (k)”
All HHS Secretary,  Defense
Secretary and DHS Secretary
actions under the authority of
this section are committed to
agency discretion.
Sec. 4 (a) “Sec. 564 (i)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (k)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (i)”
Same as S. 15 as Reported by
Committee.
Regulations Sec. 4 (a) “Sec. 564 (l)” 
The HHS Secretary may
promulgate regulations to
implement this section.
No similar provision. Sec. 4 (a) “Sec. 564 (l)” 




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 4 (a) “Sec. 564 (m)”
Nothing in this section shall
be construed to impair or
otherwise affect the authority
of — 
the President as Commander
in Chief of the Armed Forces
of the United States;
the Secretary of Defense with
respect to the Department of
Defense, including the armed
forces, under other
provisions of Federal law.
No similar provision.
Sec 4 (a) “Sec. 564 (j)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee;
Same as S. 15 as Reported by
Committee;
or the HHS Secretary under
section 319F-2 of the Public
Health Services Act to
manage the stockpile under
such section.
Sec. 4 (a) “Sec. 564 (m)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee;
Same as S. 15 as Reported by
Committee.
No similar provision.
Sec 4 (a) “Sec. 564 (j)”
Nothing in this section
impairs the authority of — 
Same as S. 15 as Reported by
Committee;
Same as S. 15 as Reported by
Committee;
the United States to use or
manage quantities of a
product that are owned or
controlled by the United
States (including quantities
in the stockpile maintained
under section 319F-2 of the
Public Health Service Act).
CRS-83
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Sec. 4 (a) “Sec. 564 (n)(1)”
With respect to members of
the armed forces, the
President may waive any
requirement designed to
ensure that individuals are
informed of an option to
accept or refuse the product
if the President determines,
in writing, that complying
with such requirement is not
feasible, is contrary to the
best interests of the members
affected, or is not in the
interests of national security. 
Sec. 4 (a) “Sec. 564 (k)(1)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564
(n)(1)(A)”
Same as S. 15 as Reported by
Committee.
















Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 







No similar provision. 
Sec. 4 (a) “Sec. 564 (n)(2)”
10 U.S.C. 1107 does not
apply for the emergency use
of products if the basis for an
emergency declaration is the
Defense Secretary’s
conclusion of a military
emergency or potential for
one under Sec. 564 (b)(1)(B).
Sec. 4 (a) “Sec. 564 (k)(2)”
If the HHS Secretary
determines that it is not
feasible to provide a member
of the armed forces 
information required by Sec.
564 (e)(1)(A)(ii) [see  above]
prior to the use of the
product, such information
will be provided to the
individual or next-of-kin as
soon as possible and within
30 days of use.  This
information must be recorded
in the medical record of the
member.
Sec. 4 (a) “Sec. 564 (k)(3)”
Same as S. 15 as Reported by
Committee.
Sec. 4 (a)  “Sec. 564
(n)(1)(B)”
Same as H.R. 2122.
Sec. 4 (a) “Sec. 564 (n)(2)”
Same as S. 15 as Reported by
Committee.
No similar provision. 





























Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




Sec. 4 (a) “Sec. 564 (o)”
If a product is the subject of
an authorization under this
section, the use of such
product within the scope of
the authorization — 
shall not be subject to any
requirements pursuant to
section 505(i) or 520(g); and




other provisions of this act.
Sec. 4 (a) “Sec. 564 (l)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee;
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (o)”
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee;
Same as S. 15 as Reported by
Committee.
Sec. 4 (a) “Sec. 564 (k)”
If a product is the subject of
an authorization under this
section, the use of such
product within the scope of
the authorization — 
shall not be considered to
constitute a clinical
investigation for purposes of
section 505(i), section
520(g);
or any other provision of this
act or section 351 of the








Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






No similar provision. Sec. 4 (a) “Sec. 564 (m)”
The HHS Secretary cannot
require any person to carry
out any activity this section
makes lawful.  People who
choose not to carry out such
activity are not required to
inform the HHS Secretary of
this choice, unless they are
the sole source of an
unapproved product that has
been authorized for
emergency use.  In this case
the manufacturer must notify
the HHS Secretary of the
choice not to participate in
the program, within a
reasonable time from the 
emergency-use authorization.
No similar provision. Sec. 4 (a) “Sec. 564 (l)”
Same as H.R. 2122.
CRS-87
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Enforce-
ment
Sec. 4 (a) “Sec. 564 (j)” 
A person who violates a
requirement of this section or
of a regulation or order
promulgated pursuant to this
section shall be subject to a
civil money penalty of not
more than $100,000 in the
case of an individual, and not
more than $250,000 in the
case of any other person, for
each violation, not to exceed
$1,000,000 for all such
violations adjudicated in a
single proceeding.
Sec. 4 (a) “Sec. 564 (n)”
A person who carries out an
activity pursuant to an
authorization under this
section, but who fails to
comply with applicable
conditions under subsection
(e), is in violation of the
Federal Food, Drug, and
Cosmetic Act.
Sec. 4 (a) “Sec. 564 (j)”




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Section 301 of the Food,
Drug and Cosmetic Act (21
U.S.C. 331) to allow
enforcement of the new Sec.
564.  
Makes it a crime to:
(1) Promote or use a product
that is the subject of an
authorization under section
564 other than as stated in
the authorization, or other
than during the period
described by section 564(g),
unless such promotion or use
is permitted under another
provision of this act;
(2) Fail to comply with an
information requirement
under section 564(e).
No similar provision. Sec. 4 (b)
Same as S. 15 as Reported by
Committee.
Same as S. 15 as Reported by
Committee.




Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 




No similar provision. No similar provision. No similar provision. Sec. 4 (b)
Subsection (d) of section
1603 of the National Defense
Authorization Act for Fiscal


































Table 5.  Required Reports
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
No similar provision. Sec. 5 Reports Regarding
Authorities Under this act.
No similar provision. Sec. 5 Reports Regarding










The HHS Secretary will
submit annual reports
regarding the exercise of the
following authorities (under
Sections 2, 3 and 4 of this
act):
use of simplified acquisition
authority,
use of other than full and
open competition,
use of expedited peer review,








Same as H.R. 2122.
Same as H.R. 2122,
Same as H.R. 2122,
Same as H.R. 2122,
Same as H.R. 2122,
 
CRS-91
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





Sec. 4 (a) “Sec. 564 (h)”
The HHS Secretary will
promptly publish in the
Federal Register, and provide
to the appropriate
congressional committees, a
notice of each authorization,
authorization termination and
authorization revocation.
Sec. 4 “Sec. 564 (b)(3)”
The HHS Secretary must
publish in the Federal






emergency use of drugs,
declaration of any
emergency, and  
conditions placed on
emergency use of drugs
emergency.
Sec. 4 (a) “Sec. 564 (h)”
Same as S. 15 as Reported by
Committee.
Sec. 4 “Sec. 564 (b)(3)”
Same as S. 15 as Reported by
Committee.
No similar provision.
Same as H.R. 2122,
Same as H.R. 2122,
Same as H.R. 2122.
The S. 15 as
Reported by
Committee










Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 







These reports will be
submitted to the designated
congressional committees
and summarize — 
the particular actions that
were taken under the
authorities specified in
subparagraph (A), including,
the identification of the threat
agent, emergency, or the
biomedical countermeasure
with respect to which the
authority was used;
the reasons underlying the
decision to use such
authorities, including any
options that were considered
and rejected with respect to





Same as H.R. 2122.
Same as H.R. 2122;
Same as H.R. 2122;
CRS-93
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






the identification of each
person or entity that
received, or was considered
and rejected for, grants,
cooperative agreements, or
contracts pursuant to the use
of such authorities; and 
whether, with respect to each
procurement that is approved
by the President, a contract
was entered into within one




the number of, nature of, and
other information concerning
the persons and entities that
received a grant, cooperative
agreement, or contract
pursuant to the use of such
authorities, and the persons
and entities that were
considered and rejected for
such a grant, cooperative
agreement, or contract,
except that the report need
not disclose the identity of
any such person or entity;
and
Same as H.R. 2122.
CRS-94
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










Sec. 5 (a)(2) 
The HHS Secretary shall
annually submit a report to
the designated congressional
committees that summarizes
the activity relating to the
exercise of the following




use of authority for personal
services contracts (including
the number of persons who
were paid amounts greater
than $100,000 and the
number of persons who were
paid amounts between
$50,000 and $100,000), and 







Same as H.R. 2122.
Same as H.R. 2122.
Same as H.R. 2122.
Same as H.R. 2122.
CRS-95
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 





No similar provision. Sec. 5 (b)(1) 
Not later than four years after
the date of the enactment of
this act, the HHS Secretary
will request the National




established in this act to
determine whether and to
what extent activities
undertaken pursuant to such
authorities have enhanced the
development of biomedical
countermeasures affecting
national security, and to
recommend any legislative or
administrative changes
necessary to improve the
ability of the Secretary to
carry out these activities in
the future. The Secretary
shall ensure that the results
of the study are submitted to
the designated congressional
committees not later than
five years after enactment.
No similar provision. No similar provision.
CRS-96
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 












This report shall include — 
a summary of the most recent
analysis by the Department
of Homeland Security and
the intelligence community




the Academy’s assessment of
the current availability of
countermeasures to address
such threats;
the Academy’s assessment of
the extent to which programs
and activities under this act
will reduce any gap between
the threat and the availability
of countermeasures to an










Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 










the Academy’s assessment of
threats to national security
that are posed by technology
that will enable, during the
10-year period beginning on
the date of the enactment of
this act, the development of
antibiotic- resistant, mutated,















 No similar provision.
CRS-98
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






Not later than four years
after the date of the
enactment of this act, the
Comptroller General of the
United States shall initiate a
study that — 
(1) describes the activities
conducted under the
authorities provided for in
section 409J(b)(1) of the
Public Health Service Act (as
added by section 2) and
section 319A-1(f)(3) and (4)




four years after the date of
the enactment of this act, the
Comptroller General of the
United States shall initiate a
study — 
(1)(A) to review the HHS
Secretary’s use of the
authorities granted under
this Act with respect to
simplified acquisition
procedures, procedures other





authority, and the purchase
of security countermeasures
under the special reserve
fund; and
(1)(B) to recommend any
legislative or administrative
changes necessary to
improve the use or
effectiveness of such
authorities in the future;
Sec. 6
Same as S. 15 as Reported by
Committee.




Same as H.R. 2122.





authorities in the future;
The
provisions














Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 








have been prohibited except
for the authorities provided
by this act; and.
(3) to assess the adequacy of
internal controls instituted by
the HHS Secretary with
respect to such authorities,
where required by this act.
No similar provision.
No similar provision.
(2)(A) to review the internal
controls instituted by the
HHS Secretary with respect
to such authorities, where
required by this act; and
(2)(B) to recommend any
legislative or administrative
changes necessary to
improve the effectiveness of
such controls; and
Same as S. 15 as Reported by
Committee;




(B)(i) to review and assess
the adequacy of the internal
controls instituted by such
Secretary with respect to
such authorities, where
required by this act; and
(B)(ii) to make
recommendations to improve
the effectiveness of such
controls;
CRS-100
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 







 No similar provision.
No similar provision.
(3)(A) to review the
Secretary’s use of the
authority granted under this
act to authorize an
emergency use of a
biomedical countermeasure,
including the means by
which the Secretary
determines whether and
under what conditions any
such authorizations should be
granted and the benefits and
adverse impacts, if  any,
resulting from the use of
such authority; and
(3)(B) to recommend  any
legislative or administrative
changes necessary to
improve the utilization or
effectiveness of such
authority and to enhance
protection of the public
health.
The results of the study shall
be submitted to the
designated congressional
committees not later than
five years after the enactment
of this act.
No similar provision.
 No similar provision.
No similar provision.





authority and to enhance
protection of the public
health;
Same as H.R. 2122.
CRS-101
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 












Not later than 120 days after
enactment of this act, the
DHS and HHS Secretaries
will jointly report to the
designated congressional
committees whether there is
a lack of adequate large-scale
biocontainment facilities
necessary for the testing of
security countermeasures in




Not later than one year after
enactment of this act, the
DHS and HHS Secretaries
shall jointly report to the
designated congressional
committees any other
potential barriers to the
procurement of security
countermeasures that have





Same as H.R. 2122.
No similar provision.
CRS-102
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 









No similar provision. Sec. 5 (e)
Not later than 270 days after
enactment of this act, the
DHS Secretary will submit to
the designated congressional
committees a report
describing the status of the
program carried out by the
Secretary to enhance the
preparedness of the United
States to respond to terrorist
attacks involving chemical
agents.
No similar provision. No similar provision.
CRS-103
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 













the House Committees on
Energy and Commerce,
Appropriations, Government
Reform, and the Select
Committee on Homeland
Security (or any successor to
the Select Committee);








Sec. 5 (d) 
Same as H.R. 2122.
Same as H.R. 2122.




















Table 6.  Outreach
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 
S. 1504 as Introduced S. 15 as Enacted Comments
Outreach No similar provision. Sec. 6
The HHS Secretary will
develop outreach measures to




and Universities and those











under sections 2 and 3 of this
act.
No similar provision. Sec. 6
The HHS Secretary will
develop outreach measures to




and Universities and those
serving large proportions of















under sections 2 and 3 of this
act.
CRS-105
Table 7.  Export Control Recommendation
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 









No similar provision. Sec. 7
Upon the award of any grant,
contract, or cooperative
agreement under section 2 or
3 of this act for the research,
development, or procurement
of a countermeasure the HHS
Secretary will, in
consultation with the heads
of other appropriate federal
agencies, determine whether
such countermeasure is
subject to existing export-
related controls and, if not,
may make a recommendation
that such countermeasure
should be included on the list
of controlled items subject to
export-related controls.
No similar provision. Sec. 7 
Same as H.R. 2122.
CRS-106
Table 8.  Interagency Coordination
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 











No similar provision. Sec. 8 (a)
The HHS, DHS and Defense
Secretaries will ensure that










such agents, analyze such
incidents, and develop
necessary countermeasures.
The Secretaries will ensure
that information and
technology possessed by
their Departments relevant to
these activities are shared
with the other Departments.
No similar provision. Sec. 8 (a)
Same as H.R. 2122.
CRS-107
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






No similar provision. Sec. 8 (b) 
The HHS, DHS and Defense
Secretaries will each
designate an officer or







and activities carried out by
their Departments.
No similar provision. Sec. 8 (b) 
Same as H.R. 2122.
CRS-108
Table 9.  Smallpox- Related Amendments to the 
Homeland Security Act and Public Health Services Act
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 













and were considered by 
other legislation. 













Table 10.  Additional HHS Secretary Authorities During 
National Emergencies
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 

















Amends section 1135(b) of
the Social Security Act that
was added by the Public
Health Security and
Bioterrorism Preparedness
and Response Act of 2002
(P.L. 107-188).
Allows the HHS Secretary in
emergencies to waive or
modify — 
sanctions relating to the
examination and treatment of
emergency medical
conditions and women in
labor, if individuals are 
directed to or relocated to
receive medical screening in
an alternative location
pursuant to an appropriate
State emergency
preparedness plan,





Same as S. 1504.
Same as S. 1504.
Same as S. 1504.
Same as S. 1504.
CRS-110
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 

















to obtain a patient’s
agreement to speak with
family members or friends;
and
to honor a request to opt out
of the facility directory;
requirement to distribute a
notice; or




Same as S. 1504.
Same as S. 1504.
Same as S. 1504.
Same as S. 1504.
CRS-111
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 









No similar provision. No similar provision. Such  waivers or
modifications shall be
limited to a 72-hour period
beginning upon
implementation of a hospital
disaster protocol. A waiver or
modification shall be
withdrawn after such period
and the provider shall
comply with the
requirements under such
paragraph for any patient still
under the care of the
provider.
Such  waivers or
modifications shall only be in
effect if such actions are
taken in a manner that does
not discriminate among
individuals on the basis of
their source of payment or of
their ability to pay, and shall
be limited to a 72-hour
period beginning upon
implementation of a hospital
disaster protocol. A waiver or
modification shall be
withdrawn after such period
and the provider shall
comply with the
requirements under such 
paragraph for any patient still
under the care of the
provider.
CRS-112
Table 11.  Special Funding Language
Provision S. 15 as Reported by
Committee
H.R. 2122 as Passed by
House 






No similar provision. No similar provision. Sec. 7
In the Senate, for purposes of
points of order under a
concurrent resolution on the
budget and the Congressional
Budget Act of 1974,
provisions contained in any
bill, resolution, amendment,
motion, or conference report
that change the availability of
any amounts appropriated
pursuant to this act (or an
amendment made by this act)
shall not be scored with
respect to the level of budget
authority or outlays
contained in such bill,
resolution, amendment,
motion, or conference report.
No similar provision.
